

Recent patent applications in angiogenesis research

Patent #	Subject	Assignee(s)	Inventor(s)	Priority application date	Publication date
WO 2005116066	A new peptide of 5 to 40 amino acids from a portion of decorin, which contains leucine-rich repeats (LRRs), or its variant; useful for treating angiogenesis in cancer, diabetic retinopathy, macular degeneration, rheumatoid arthritis, ulcers, endometriosis and psoriasis.	National University of Singapore	Ge R, Kini M	5/31/2004	12/8/2005
WO 2005115407	An agent that activates constitutive nitric oxide synthase by inhibitor displacement; useful in the treatment of diseases modulated by nitric oxide synthase activity, e.g., hypertension, angiogenesis, diabetes, emphysema, atherosclerosis and asthma.	Rensselaer Polytechnic Institute (Troy, NY, USA)	Salerno JC, Smith SME	5/26/2004	12/8/2005
US 20050272696	A method of inhibiting or preventing a disease/condition, comprising identifying a disease or condition in a patient, selecting a glycosaminoglycan polymer and providing a composition comprising recombinantly produced defined glycosaminoglycan polymers with a desired specific size distribution. The composition is claimed to inhibit angiogenesis.	University of Oklahoma (Norman, OK, USA)	DeAngelis PL	4/2/1998	12/8/2005
US 20050271667	An antibody that specifically binds to an endothelial-derived gene (EG-1) encoded peptide; useful for inhibiting angiogenesis and tumorigenesis.	Regents of the University of California (Oakland, CA, USA)	Nguyen MH	4/15/2005	12/8/2005
WO 2005116131	A product comprising hyaluronic acid or its salt, useful for treating, e.g., osteoarthritis, ophthalmological disease and cancer (as an angiogenesis inhibitor).	Novozymes Biopolymer (Bagsværd, Denmark)	Back P, Thwaites E, Bach P	2/15/2005	12/8/2005
JP 2005336080	A method for separating and recovering cells for angiogenic treatments by pouring raw material cell sap comprising cells effective for angiogenesis on a trapping filter and recovering the trapped cells.	Asahi Medical Co. Ltd. (Tokyo)	Hori T, Shiota Y	5/26/2004	12/8/2005
WO 2005113828	A method of diagnosing cancer, comprising detecting the overexpression of A3 receptor protein in a sample compared to the level in a healthy mammal. A3 is a receptor antagonist and angiogenesis inhibitor.	King Pharmaceuticals Research & Development (Bristol, TN, USA)	Borea PA, Gessi S, Leung E, Liboni A, MacLennan S	5/14/2004	12/1/2005
WO 2005112569	A method for delivering a therapeutic agent to adventitia of a vessel for the treatment of a vascular condition (e.g., anti-inflammatory, angiogenesis inhibitor), involving forming the therapeutic agent into microparticles and dispersing them throughout a liquid carrier to form a therapeutic mixture for delivery by microsyringe.	Medtronic Vascular (Santa Rosa, CA, USA)	Cheng P, Judd D, Patel K, Sundar RR, Tedeschi E, Tremble P, Udipi K	5/13/2004	12/1/2005
US 20050267062	A method for treating an ischemic condition or modulating angiogenesis in a subject, comprising introducing a nucleic acid encoding a polypeptide comprising a zinc finger DNA-binding domain and a transcriptional activation domain.	Sangamo Biosciences (Richmond, CA, USA)	Eisenberg SP, Jamieson A, Jarvis E, Liu P, Liu Q, Rebar E, Wolffe A	12/6/2001	12/1/2005
WO 2005113596	New polypeptides, specifically isoforms of cell surface receptors such as EphA, VEGF, MET, RON, CSF, etc.; useful in treating cancer and inflammatory, infectious, angiogenesis-related conditions or immune disorders.	Receptor Biologix (S. San Francisco, CA, USA)	Jin P, Shepard MH	3/30/2005	12/1/2005
WO 2005110407	The dispersion of nanoparticles comprising a lactam compound, at least one stabilizer and liquid medium; inhibits angiogenesis and useful for treating, e.g., cancer, Alzheimer disease and rheumatoid arthritis.	Bristol-Myers Squibb (New York), Elan Pharma (Princeton, NJ, USA)	Franchini MK, Haby TA, Liversidge E	5/18/2004	11/24/2005
US 20050261316	New substituted purine-2,6-dione compounds that are adenosine receptor A-2B inhibitors; useful for treating, e.g., atherosclerosis, angiogenesis, type II diabetes, cancer, asthma, inflammatory gastrointestinal tract disorders and neurological disorders.	Elzein E, Ibrahim P, Kalla R, Li X, Palle V, Perry T, Varkhedkar V, Xiao D, Zablocki J	Elzein E, Ibrahim P, Kalla R, Li X, Palle V, Perry T, Varkhedkar V, Xiao D, Zablocki J	7/25/2005	11/24/2005

Source: Thomson Scientific Search Service (formerly Derwent). The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1725 Duke Street, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) DERWENT (<http://www.thomson.com/scientific>).